Suppr超能文献

草药抑制剂 SARS-CoV-2 M 可有效改善小鼠的急性肺损伤。

Herbal inhibitors of SARS-CoV-2 M effectively ameliorate acute lung injury in mice.

机构信息

State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, Department of Biochemistry, School of Basic Medicine Peking Union Medical College, Beijing, China.

National Kunming High-level Biosafety Primate Research Center, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Yunnan, China.

出版信息

IUBMB Life. 2022 Jun;74(6):532-542. doi: 10.1002/iub.2616. Epub 2022 Apr 22.

Abstract

Coronavirus disease 2019, a newly emerging serious infectious disease, has spread worldwide. To date, effective drugs against the disease are limited. Traditional Chinese medicine was commonly used in treating COVID-19 patients in China. Here we tried to identify herbal effective lipid compounds from the lipid library of 92 heat-clearing and detoxication Chinese herbs. Through virtual screening, enzymatic activity and inhibition assays, and surface plasmon resonance tests, we identified lipid compounds targeting the main protease (M ) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and verified their functions. Here, we found that natural lipid compounds LPC (14:0/0:0) and LPC (16:0/0:0) could target SARS-CoV-2 M , recover cell death induced by SARS-CoV-2, and ameliorate acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) induced by bacterial lipopolysaccharides and virus poly (I:C) mimics in vivo and in vitro. Our results suggest that LPC (14:0/0:0) and LPC (16:0/0:0) might be potential pan remedy against ARDS.

摘要

新型冠状病毒病(COVID-19)是一种新出现的严重传染病,已在全球范围内传播。迄今为止,针对该疾病的有效药物有限。中药在中国常用于治疗 COVID-19 患者。在这里,我们试图从 92 种清热解毒中药的脂质库中鉴定针对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)主要蛋白酶(M )的草药有效脂质化合物。通过虚拟筛选、酶活性和抑制测定以及表面等离子体共振试验,我们鉴定了针对 SARS-CoV-2 M 的脂质化合物,并验证了它们的功能。在这里,我们发现天然脂质化合物 LPC(14:0/0:0)和 LPC(16:0/0:0)可以靶向 SARS-CoV-2 M ,恢复由 SARS-CoV-2 诱导的细胞死亡,并改善由细菌脂多糖和病毒多聚(I:C)模拟物在体内和体外诱导的急性肺损伤(ALI)/急性呼吸窘迫综合征(ARDS)。我们的研究结果表明,LPC(14:0/0:0)和 LPC(16:0/0:0)可能是治疗 ARDS 的潜在泛疗法。

相似文献

2
Nitazoxanide and COVID-19: A review.硝唑尼特与 COVID-19:综述。
Mol Biol Rep. 2022 Nov;49(11):11169-11176. doi: 10.1007/s11033-022-07822-2. Epub 2022 Sep 12.
3
The role of berberine in Covid-19: potential adjunct therapy.小檗碱在新冠病毒肺炎中的作用:一种潜在的辅助治疗方法。
Inflammopharmacology. 2022 Dec;30(6):2003-2016. doi: 10.1007/s10787-022-01080-1. Epub 2022 Oct 2.
4
Effective inhibition of coronavirus replication by .通过. 有效抑制冠状病毒复制。
Front Biosci (Landmark Ed). 2021 Oct 30;26(10):789-798. doi: 10.52586/4988.
6
Ursolic acid and SARS-CoV-2 infection: a new horizon and perspective.熊果酸与 SARS-CoV-2 感染:新的视野和展望。
Inflammopharmacology. 2022 Oct;30(5):1493-1501. doi: 10.1007/s10787-022-01038-3. Epub 2022 Aug 3.

本文引用的文献

3
COVID-19: Discovery, diagnostics and drug development.新型冠状病毒肺炎:发现、诊断和药物研发。
J Hepatol. 2021 Jan;74(1):168-184. doi: 10.1016/j.jhep.2020.09.031. Epub 2020 Oct 8.
4
SARS-CoV-2 vaccines in development.正在研发中的 SARS-CoV-2 疫苗。
Nature. 2020 Oct;586(7830):516-527. doi: 10.1038/s41586-020-2798-3. Epub 2020 Sep 23.
5
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
9
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病:考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验